MediWound Q2 Revenue Jumps 43%, Gross Margin Improves to 23.5%

MediWound's Q2 revenue increased 43% QoQ to $5.7mln, driven by higher product sales and a favorable mix. The company advanced its Phase III EscharEx VALUE trial, expanded NexoBrid's U.S. presence, and continued scaling manufacturing to meet global demand. Strategic partnerships with ConvaTec, SCT, Solventum, Mölnlycke, and others support EscharEx validation and position MediWound for further growth and regulatory progress.

MediWound Ltd. (NASDAQ: MDWD), a leader in enzymatic therapeutics for tissue repair, reported its second-quarter 2025 financial results with revenue of $5.7 million, representing a 43% quarter-over-quarter increase [1]. The company highlighted progress in its VALUE Phase III trial of EscharEx® for venous leg ulcers and established new strategic partnerships with Essity and Convatec.

Key developments include NexoBrid®'s 52% year-over-year U.S. revenue growth and ongoing manufacturing expansion expected to increase production capacity six-fold by year-end 2025. The company received an additional $3.6 million in DoD funding for NexoBrid development. Financial results showed a net loss of $13.3 million, with cash reserves of $32.9 million as of June 30, 2025.

The VALUE Phase III trial of EscharEx® in venous leg ulcers continued to enroll patients, while NexoBrid® manufacturing expansion remained on track to meet anticipated growth in demand. The company's gross margin improved to 23.5% from 8.8% year-over-year.

MediWound's Chief Executive Officer, Ofer Gonen, stated, "The VALUE Phase III trial of EscharEx® is actively recruiting patients, and with the addition of Convatec and Essity to our clinical partnerships, we are now collaborating with all relevant leading global wound care companies. In the U.S., NexoBrid® is gaining commercial traction, and our manufacturing expansion remains on track to meet the anticipated growth in demand. The solid progress in the first half of 2025 reinforces our confidence in our long-term strategy and our commitment to value creation."

The company's cash reserves stood at $32.9 million as of June 30, 2025, compared to $43.6 million as of December 31, 2024. During the first half of 2025, MediWound used $11.9 million to fund operations, including $2.3 million in capital expenditures primarily related to manufacturing scale-up. MediWound received $0.7 million in proceeds from the exercise of Series A warrants during the quarter, with an additional $1.8 million received after quarter-end.

MediWound management will host a conference call for investors on Thursday, August 14, 2025, beginning at 8:30 a.m., Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-844-676-8833 (in the U.S.), 1-80-921-2373 (Israel), or 1-412-634-6869 (outside the U.S. & Israel). The call will be available via webcast by clicking HERE or on the Events & Presentations page of Company’s website.

A replay of the call will be available on the Company’s website at

References:
[1] https://www.stocktitan.net/news/MDWD/medi-wound-reports-second-quarter-2025-financial-results-and-z8ap6oexluul.html
[2] https://seekingalpha.com/news/4484756-mediwound-q2-2025-earnings-preview